EUVIMEDEUVIMED entdecken
Crossref

Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Marinde J G Bond iD, Maarten van Smeden, Koen Degeling, Chiara Cremolini iD, Hans-Joachim Schmoll iD, Carlotta Antoniotti iD, Sara Lonardi iD, Sabina Murgioni iD, Daniele Rossini iD, Stefan Ibach, Miriam Koopman iD, Rutger-Jan Swijnenburg und 3 weitere

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci.24.00037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Marinde J G Bond und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the N…. Hauptthemen laut MEDLINE: Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Leucovorin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patient outcomes may differ from randomized trial averages. We aimed to predict benefit from FOLFOXIRI versus infusional fluorouracil, leucovorin, and oxaliplatin/fluorouracil, leucovorin, and irinotecan (FOLFOX/FOLFIRI), both plus bevacizumab, in patients with metastatic colorectal cancer (mCRC). METHODS A Cox model with prespecified clinical, molecular, and laboratory variables was developed in 639 patients from the TRIBE2 trial for predicting 2-year mortality. Data from the CHARTA (n = 232), TRIBE1 (n = 504), and CAIRO5 (liver-only mCRC, n = 287) trials were used for external validation and heterogeneity of treatment effects (HTE) analysis. This involves categorizing patients into risk groups and assessing treatment effects across these groups. Performance was assessed by the C-index and calibration plots. The C-for-benefit was calculated to assess evidence for HTE. The c-for-benefit is specifically designed for HTE analysis. Like the commonly known c-statistic, it summarizes the discrimination of a model. Values over 0.5 indicate evidence for HTE. RESULTS In TRIBE2, the overoptimism-corrected C-index was 0.66 (95% CI, 0.63 to 0.69). At external validation, the C-index was 0.69 (95% CI, 0.64 to 0.75), 0.68 (95% CI, 0.64 to 0.72), and 0.65 (95% CI, 0.65 to 0.66), in CHARTA, TRIBE1, and CAIRO5, respectively. Calibration plots indicated slight underestimation of mortality. The c-for-benefit indicated evidence for HTE in CHARTA (0.56, 95% CI, 0.48 to 0.65), but not in TRIBE1 (0.49, 95% CI, 0.44 to 0.55) and CAIRO5 (0.40, 95% CI, 0.32 to 0.48). CONCLUSION Although 2-year mortality could be reasonably estimated, the HTE analysis showed that clinically available variables did not reliably identify which patients with mCRC benefit from FOLFOXIRI versus FOLFOX/FOLFIRI, both plus bevacizumab, across the three studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsLeucovorinFluorouracilCamptothecinOrganoplatinum CompoundsHumansMaleFemaleMiddle AgedAgedNeoplasm MetastasisTreatment OutcomePrognosisProportional Hazards ModelsAdult

Substanzen

BevacizumabLeucovorinFluorouracilCamptothecinOrganoplatinum Compounds

Autor:innen und Institutionen

  • Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Cancer Health Services Research, Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
  • Cancer Health Services Research, Centre for Health Policy, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
  • Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, University Hospital of Pisa, Pisa, Italy.
  • Department of Oncology, University Hospital of Pisa, Pisa, Italy.
  • Department of Clinical Hematology-Oncology, University Clinic Halle, Martin Luther University, Halle, Germany.

ORCID-Profile: Marinde J G Bond, Chiara Cremolini, Hans-Joachim Schmoll, Carlotta Antoniotti, Sara Lonardi, Sabina Murgioni, Daniele Rossini, Miriam Koopman, Cornelis J A Punt, Anne M May, Johannes J M Kwakman

Zitieren

APA

Bond, M. J. G., van Smeden, M., Degeling, K., Cremolini, C., Schmoll, H. J., Antoniotti, C., Lonardi, S., Murgioni, S., Rossini, D., Ibach, S., Koopman, M., Swijnenburg, R. J., Punt, C. J. A., May, A. M., & Kwakman, J. J. M. (2024). Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00037

Vancouver

Bond MJG, van Smeden M, Degeling K, Cremolini C, Schmoll HJ, Antoniotti C, et al. Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.24.00037

BibTeX
@article{Bond2024,
  author = {Bond, Marinde J G and van Smeden, Maarten and Degeling, Koen and Cremolini, Chiara and Schmoll, Hans-Joachim and Antoniotti, Carlotta and Lonardi, Sara and Murgioni, Sabina and Rossini, Daniele and Ibach, Stefan and Koopman, Miriam and Swijnenburg, Rutger-Jan and Punt, Cornelis J A and May, Anne M and Kwakman, Johannes J M},
  title = {Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci.24.00037}
}
Kostenlos starten →